MedCap AB

As of June 30, 2026, MedCap AB carries a market capitalization of 7.85B, placing it among publicly traded companies globally. Its enterprise value stands at 8.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MedCap AB's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, MedCap AB has 14.98M shares outstanding.

As of June 30, 2026, MedCap AB trades at a trailing price-to-earnings ratio of 32.35. The price-to-sales ratio is 3.46, and the price-to-book ratio stands at 4.95.

As of June 30, 2026, MedCap AB trades at an EV/EBITDA multiple of 15.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.95 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. MedCap AB trades at an EV/FCF ratio of 21.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 8.03B versus a market cap of 7.85B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MedCap AB maintains a current ratio of 1.86, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.82, indicating elevated leverage, while an interest coverage ratio of 10.91 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MedCap AB posted a return on equity (ROE) of 16.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.19 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.10, useful for judging operating efficiency across full business cycles. The company generates approximately 3.64M in revenue per employee across its workforce of 625.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.12 indicates how many times MedCap AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, MedCap AB recorded 71.90M in income tax expense. That works out to an effective tax rate of 22.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 315.70M, leaving 243.20M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, MedCap AB's stock has declined approximately 2.15% over the past 52 weeks. The 50-day moving average sits at 537.96, while the 200-day moving average is 514.60.

Over the twelve months ended June 30, 2026, MedCap AB generated 2.28B in revenue and converted that into 243.20M in net income, yielding earnings per share of 16.23. EBITDA reached 524.90M, while operating income came in at 350.00M.

As of June 30, 2026, MedCap AB holds 286.30M in cash and equivalents against 457.60M in total debt, resulting in a net debt position of -80.80M. Total book value stands at 1.59B, with working capital of 472.40M providing operational flexibility.

MedCap AB produced 399.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -67.80M in capital expenditures, free cash flow totaled 332.00M - equivalent to 22.13 per share.

Over the twelve months ended June 30, 2026, MedCap AB posted a gross margin of 59.69, reflecting its pricing power and cost economics. The operating margin of 15.38 and net profit margin of 10.69 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 4.22, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MedCap AB shareholders.

MedCap AB's most recent stock split took place on September 27, 2016 with a 10:1 split ratio.